U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Institute of Medicine (US) Committee to Study Medication Development and Research at the National Institute on Drug Abuse; Fulco CE, Liverman CT, Earley LE, editors. Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington (DC): National Academies Press (US); 1995.

Cover of Development of Medications for the Treatment of Opiate and Cocaine Addictions

Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector.

Show details

Acknowledgments

The committee appreciates the expert support of the IOM project staff, former division director, Division of Biobehavioral Sciences and Mental Disorders (BSMD), Robert Cook-Deegan and Constance Pechura, current BSMD director, for their practical comments and guidance during the committee's deliberations. We thank study director, Carolyn Fulco for her contributions to the structure and substance of the report and in preliminary editing of this document. We are indebted to Catharyn Liverman for her excellent research skills in collecting, analyzing, and presenting a range of information, in addition to verifying all committee references; project assistant, Terri Barba for providing logistical assistance for the workshop and all committee meetings, and for overseeing report production; and Mary Ann Racin for preparing the camera-ready copy of the report.

The committee benefitted from the expertise of Miriam Davis and her input into the committee's deliberations and of Robert Talbot-Stern, consultants to the committee. The committee wishes to express its sincere appreciation to Geoffrey M. Levitt for his excellent research and expert legal advice. The committee appreciates the overall editing by Norman Grossblatt and Kate Kelly; and the assistance of Claudia Carl in guiding the report through review.

The IOM staff and the committee appreciate the thoughtful input and contribution of Charles Grudzinskas and his staff at NIDA. We are also indebted to the many representatives of federal agencies, congressional staff, academia, advocacy groups, professional organizations, and the pharmaceutical industry who shared their expertise with the committee. Those individuals are acknowledged in Appendix A.

Copyright 1995 by the National Academy of Sciences. All rights reserved.
Bookshelf ID: NBK232171

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.5M)
  • Disable Glossary Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...